Middle-East and Africa Cancer Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Middle -East and Africa Cancer Vaccines Market is segmented by Technology (Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines and Other Technologies), Treatment Method, Application and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
CAGR: 9.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The incidence of cancer is increasing every year, which has primarily increased the demand for vaccines in research and development for cancers. The cancer is found damaging the immune system, as cancer cells produce self-antigen. The cancer vaccines thus play a vital role in the maintenance of the immune system, as they are considered to be biological response modifiers. 

These cancer vaccines target the infectious agents that may cause cancer, through the production of the antibodies. Cancer vaccines are thus considered to be a new therapy and are not popular, as compared to the other alternative therapeutic drugs. However, cancer vaccines have shown great potential in both preventive and therapeutic ways. 

Moreover, healthcare physicians are looking for alternate therapies, due to the huge burden of cancer cases and the side effects of the present therapies. Hence, the market for cancer vaccines is expected to grow at a high rate, during the forecast period.

Scope of the report

As per the scope of the report, cancer vaccines are defined as the vaccines developed to prevent or treat existing cancers, by strengthening the body’s natural immune response system against cancer. These cancer vaccines belong to a class of substances, known as biological response modifiers. These modifiers work by stimulating or restoring the immune system’s ability to fight against diseases.

By Technology
Recombinant Cancer Vaccines
Whole-cell Cancer Vaccines
Viral Vector and DNA Cancer Vaccines
Other Technologies
By Treatment Method
Preventive Vaccine
Therapeutic Vaccine
By Application
Prostate Cancer
Cervical Cancer
Other Applications (Liver, Skin, etc.)
Middle-East & Africa
South Africa
Rest of Middle-East & Africa

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cervical Cancer Segment is Expected to grow Fastest During the Forecast Period

The increasing prevalence of cervical cancer in the region is considered to be the major driving factor for the market growth. According to Globocan 2018, 11.3 % of cancers are cervical cancer, i. e 119,284 cases have been registered for the year 2018 in Africa. With this huge patient pool and a huge scope of the market, many major players are also looking into investing in the region. 

Furthermore, high-quality, sustainable projects, such as in Eldoret (AMPATH Oncology) the work of Hospice Africa Uganda, the collaborations between Crumlin Children’s Hospital (Dublin, Ireland) and the Muhimbili University of Health and Allied Sciences (Dar-es-Salaam) Tanzania, etc. contributes in a positive manner towards cancer control thereby boosting the cancer vaccine market.

MEA cancer

Competitive Landscape

The Middle East and Africa Cancer Vaccines Market are moderately competitive with several major players. Some of the strategies implemented include agreements, collaborative models, business expansion, and product developments. Some of the major players are Astellas Pharma Inc., AstraZeneca PLC, Merck & Co. Inc, GlaxoSmithKline, Bristol-Myers Squibb. 

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Number of Cancer Cases

      2. 4.2.2 Technological Developments in Cancer Vaccines

    3. 4.3 Market Restraints

      1. 4.3.1 Presence of Alternative Therapies

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Technology

      1. 5.1.1 Recombinant Cancer Vaccines

      2. 5.1.2 Whole-cell Cancer Vaccines

      3. 5.1.3 Viral Vector and DNA Cancer Vaccines

      4. 5.1.4 Other Technologies

    2. 5.2 By Treatment Method

      1. 5.2.1 Preventive Vaccine

      2. 5.2.2 Therapeutic Vaccine

    3. 5.3 By Application

      1. 5.3.1 Prostate Cancer

      2. 5.3.2 Cervical Cancer

      3. 5.3.3 Other Applications (Liver, Skin, etc.)

    4. 5.4 Geography

      1. 5.4.1 Middle-East & Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East & Africa


    1. 6.1 Company Profiles

      1. 6.1.1 Astellas Pharma Inc.

      2. 6.1.2 AstraZeneca PLC

      3. 6.1.3 Merck & Co. Inc.

      4. 6.1.4 GlaxoSmithKline PLC

      5. 6.1.5 Bristol-Myers Squibb

      6. 6.1.6 Dendreon

      7. 6.1.7 Sanofi SA

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Middle East and Africa Cancer Vaccines Market market is studied from 2018 - 2026.

The Middle East and Africa Cancer Vaccines Market is growing at a CAGR of 9.6% over the next 5 years.

AstraZeneca PLC, Merck & Co. Inc., GlaxoSmithKline, Bristol-Myers Squibb, Astellas Pharma Inc. are the major companies operating in Middle East and Africa Cancer Vaccines Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!